news.google.com· FierceBiotech·· 1 day agoPickScore71
GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial - Fierce Biotech
In brief
GSK's B7-H3 ADC achieved a 67% reduction in cancer risk in Hansoh Pharma's phase 3 trial in China. The available material provides only headline information, without a specific drug name, trial name, sample size, or statistical interval.
Why it matters
The brief gives trial stage, region, and the 67% risk reduction to identify late-stage B7-H3 ADC results for further review.
Source: news.google.com · news.google.com